文献速递消化系统肿瘤

PERISCOPE II 最终结果:胃切除联合 CRS 与 HIPEC 对比单纯全身治疗用于胃癌局限性腹膜转移

Systemic therapy, gastrectomy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy versus systemic therapy alone for gastric cancer with limited peritoneal metastases (PERISCOPE II): final results of a multicentre, randomised, controlled, phase 3 trial after an unplanned commissioned interim analysis.
PubMed 文献 · Lancet Oncol · 2026-07-08

这项欧洲多中心随机对照 3 期试验纳入 102 例经三线以上全身治疗后无进展、可切除 cT3/cT4a 胃腺癌且腹膜癌指数<7 或腹膜细胞学阳性的成人患者,比较胃切除联合减瘤手术与奥沙利铂/多西他赛 HIPEC 对比继续全身治疗。

要点

  • 胃切除联合 CRS 与 HIPEC 较单纯全身治疗未改善局限性腹膜转移胃癌的总生存。
  • 实验组 3 级及以上不良事件发生率 42%,高于标准组的 20%。
  • 实验组发生 3 例治疗相关死亡,分别归因于 ARDS、吻合口漏和出血。

核心结论

  • 对于胃癌合并局限性腹膜转移患者,胃切除联合减瘤手术与 HIPEC 相比单纯全身治疗未带来生存获益。

研究设计与样本

  • 欧洲 8 家三级转诊医院开展的多中心、随机、对照、3 期试验(PERISCOPE II),按 1:1 随机分组并按中心、组织学亚型和腹膜转移范围分层。
  • 纳入年龄≥18 岁、可切除 cT3 或 cT4a 胃腺癌、腹膜癌指数<7 或腹膜细胞学阳性或两者兼有、且接受≥3 周期全身治疗后无疾病进展的成人患者。
  • 共纳入 102 例参与者(每组 51 例),中位年龄 60 岁(IQR 51–69),男性 58 例(57%)、女性 43 例(43%),白人 86 例(85%)。
  • 主要终点为总生存期,按意向性治疗原则计算;试验因无效性期中分析提前终止(ClinicalTrials.gov NCT03348150)。

主要发现

  • 中位随访 67 个月(IQR 47–73)。
  • 标准组 51 例中 10 例(20%)、实验组 50 例中 21 例(42%)发生 3 级及以上不良事件。
  • 实验组最常见 3 级及以上不良事件为贫血(4 例,8%)和肝酶升高(4 例,8%);标准组为恶心(2 例,4%)、肝酶升高(2 例,4%)和电解质紊乱(2 例,4%)。
  • 标准组 51 例中 3 例(6%)、实验组 50 例中 22 例(44%)发生严重不良事件;随机化后 100 天内实验组发生 3 例治疗相关死亡,分别归因于急性呼吸窘迫综合征、吻合口漏和出血。

关键数值与推荐

  • 实验组 HIPEC 方案为奥沙利铂 460 mg/m2(41°C)联合多西他赛 50 mg/m2(37°C)。
  • 入组条件包括腹膜癌指数<7 或腹膜细胞学阳性或两者兼有,且接受≥3 周期全身治疗后无疾病进展。

临床怎么用

  • 对于胃癌局限性腹膜转移患者,不应在全身治疗基础上常规加用胃切除联合减瘤手术与 HIPEC 以追求生存获益。
  • 选择该联合治疗时需权衡更高的 3 级及以上不良事件、严重不良事件及治疗相关死亡风险。

局限性

  • 试验因无效性期中分析提前终止,实际样本量仅 102 例。
  • 随访中位 67 个月,但提前终止可能影响长期结局的完整评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) is widely used for patients with gastric cancer and peritoneal metastases. However, the efficacy of this treatment has never been compared with that of systemic therapy. We aimed to investigate the efficacy of gastrectomy with cytoreductive surgery and HIPEC for patients with gastric cancer and limited peritoneal metastases, compared with systemic therapy alone. METHODS: In this European, multicentre, randomised, controlled, phase 3 trial (PERISCOPE II) in eight European tertiary referral hospitals, we recruited adults (aged ≥18 years) with resectable cT3 or cT4a gastric adenocarcinoma who had limited peritoneal metastases (Peritoneal Cancer Index <7) or tumour-positive peritoneal cytology, or both, in the absence of disease progression after three or more cycles of systemic therapy. Participants were randomly allocated (1:1) to the standard group (continuation of systemic therapy) or the experimental group (gastrectomy plus cytoreductive surgery and HIPEC with oxaliplatin [460 mg/m2 at 41°C] and docetaxel [50 mg/m2 at 37°C]), stratified by centre, histological subtype, and extent of peritoneal metastases. The primary endpoint was overall survival, calculated following the intention-to-treat principle. This trial is registered with ClinicalTrials.gov, NCT03348150, and was closed prematurely due to an unplanned interim analysis for futility. FINDINGS: Between Nov 6, 2017 and Aug 21, 2024, 102 participants were recruited (51 per group). Median age was 60 years (IQR 51-69); 58 (57%) participants were men, 43 (43%) were women, and 86 (85%) were White. Median follow-up was 67 months (IQR 47-73). Median overall survival in the standard group was 16·6 months (95% CI 14·1-21·9), compared with 15·7 months (11·4-25·5) in the experimental group (hazard ratio 1·10 [95% CI 0·69-1·74]; p=0·70). Ten (20%) of 51 patients in the standard group and 21 (42%) of 50 patients in the experimental group had grade 3 or worse adverse events. The most common grade 3 or worse adverse events were anaemia (four [8%] patients) and elevated liver enzymes (four [8%]) in the experimental group, and nausea (two [4%]), elevated liver enzymes (two [4%]), and electrolyte disturbances (two [4%]) in the standard group. Three (6%) of 51 patients in the standard group and 22 (44%) of 50 patients in the experimental group had serious adverse events. At 100 days after randomisation, three treatment-related deaths had occurred, all in the experimental group and attributed to acute respiratory distress syndrome (one patient), anastomotic leakage (one patient), and bleeding (one patient). INTERPRETATION: Gastrectomy with cytoreductive surgery and HIPEC provided no survival benefit in patients with gastric cancer and limited peritoneal metastases compared with systemic therapy alone. FUNDING: The Dutch Cancer Society, the Netherlands Organisation for Health Research and Development, the Dutch Ministry of Health, Henk Boot, the Bengt Ihre Research Foundation, and the Swedish Cancer Society.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Quik JSE, Vollebergh MA, Retèl VP, et al. Systemic therapy, gastrectomy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy versus systemic therapy alone for gastric cancer with limited peritoneal metastases (PERISCOPE II): final results of a multicentre, randomised, controlled, phase 3 trial after an unplanned commissioned interim analysis. Lancet Oncol. 2026. PMID: 42419336. doi:10.1016/S1470-2045(26)00144-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。